MeSH term
Frequency | Condition_Probility | Adolescent | 15 | 0.0 |
Adult | 47 | 0.0 |
Aged | 33 | 0.0 |
Aged, 80 and over | 7 | 0.0 |
Antigens, CD/*analysis/genetics | 2 | 8.0 |
English Abstract | 13 | 0.0 |
Female | 66 | 0.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Humans | 216 | 0.0 |
Immunohistochemistry | 17 | 0.0 |
Male | 65 | 0.0 |
Middle Aged | 38 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
Prognosis | 14 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Immunologic Memory | 3 | 1.0 |
Immunophenotyping | 36 | 1.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
Lymphocyte Activation | 8 | 0.0 |
Research Support, Non-U.S. Gov't | 130 | 0.0 |
Base Sequence | 12 | 0.0 |
Candidiasis/microbiology | 2 | 33.0 |
DNA Fingerprinting/*methods | 2 | 3.0 |
Genotype | 3 | 0.0 |
Karyotyping | 12 | 0.0 |
Molecular Sequence Data | 20 | 0.0 |
Polymerase Chain Reaction | 10 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 21 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Antigens, CD/metabolism | 4 | 0.0 |
Flow Cytometry | 29 | 0.0 |
P-Selectin/*metabolism | 2 | 9.0 |
Tumor Cells, Cultured | 27 | 0.0 |
Blotting, Northern | 7 | 0.0 |
Blotting, Western | 5 | 0.0 |
Carcinoma, Small Cell/*genetics | 2 | 3.0 |
*Gene Expression Profiling | 8 | 1.0 |
Lung Neoplasms/*genetics | 2 | 0.0 |
Mutation | 2 | 0.0 |
Antigens, CD/genetics | 3 | 2.0 |
Cells, Cultured | 18 | 0.0 |
DNA-Binding Proteins/genetics | 4 | 0.0 |
*Membrane Glycoproteins | 55 | 6.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Transcription Factors/genetics | 4 | 0.0 |
Animals | 41 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Mice | 33 | 0.0 |
Oligonucleotide Array Sequence Analysis | 6 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
Antigens, CD/*metabolism | 10 | 1.0 |
Cell Adhesion | 6 | 0.0 |
Membrane Glycoproteins/*metabolism | 2 | 0.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
Rats | 9 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Acute Disease | 3 | 0.0 |
Antigens, CD/analysis | 17 | 1.0 |
Antigens, Neoplasm/analysis | 12 | 3.0 |
Fluorescent Dyes | 3 | 0.0 |
Immunophenotyping/*methods | 4 | 5.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 3 | 1.0 |
Diagnosis, Differential | 6 | 0.0 |
Reference Values | 5 | 0.0 |
Antigens, CD/*immunology | 7 | 1.0 |
Cross Reactions | 2 | 0.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Comparative Study | 12 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
In Situ Hybridization | 4 | 0.0 |
Apoptosis/*immunology | 2 | 1.0 |
Cell Membrane/immunology/metabolism | 2 | 1.0 |
Glycosylphosphatidylinositols/*metabolism | 2 | 3.0 |
Signal Transduction/*immunology | 2 | 0.0 |
Binding Sites | 3 | 0.0 |
Glycosylphosphatidylinositols/metabolism | 3 | 5.0 |
Kinetics | 3 | 0.0 |
Leukocyte L1 Antigen Complex | 2 | 3.0 |
Mice, Inbred C57BL | 6 | 0.0 |
Leukocytes, Mononuclear/immunology | 2 | 0.0 |
Lymphocyte Activation/*immunology | 2 | 0.0 |
Blood Platelets/metabolism | 2 | 1.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Cell Movement/*physiology | 2 | 0.0 |
Glycosylation | 5 | 0.0 |
Phosphatidylinositol Diacylglycerol-Lyase | 2 | 2.0 |
Transfection | 6 | 0.0 |
HLA-DR Antigens/analysis | 6 | 0.0 |
*Immunophenotyping | 4 | 2.0 |
Leukemia, Hairy Cell/*diagnosis/immunology | 2 | 66.0 |
Staining and Labeling | 2 | 0.0 |
Survival Analysis | 5 | 0.0 |
Tumor Markers, Biological/metabolism | 2 | 0.0 |
Bone Marrow Transplantation | 2 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Transduction, Genetic/genetics | 2 | 22.0 |
*Chromosome Mapping | 3 | 0.0 |
*Chromosomes, Human, Pair 6 | 2 | 0.0 |
Expressed Sequence Tags | 3 | 0.0 |
Gene Library | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Models, Genetic | 3 | 0.0 |
*Apoptosis | 3 | 0.0 |
DNA, Neoplasm/analysis | 3 | 0.0 |
Immunoenzyme Techniques | 13 | 0.0 |
Kidney Neoplasms/chemistry/*pathology | 2 | 28.0 |
Tumor Markers, Biological/*analysis | 7 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Incidence | 2 | 0.0 |
Risk Factors | 2 | 0.0 |
Survival Rate | 4 | 0.0 |
Antigens, CD/*genetics | 5 | 1.0 |
Biological Markers | 7 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Gene Therapy | 2 | 0.0 |
Retroviridae/genetics | 2 | 0.0 |
Antibody Specificity | 5 | 0.0 |
In Vitro | 6 | 0.0 |
B-Lymphocytes/*cytology | 2 | 3.0 |
Cell Differentiation/drug effects | 6 | 0.0 |
Cell Lineage | 4 | 0.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Infant | 7 | 0.0 |
Ligands | 4 | 0.0 |
Membrane Proteins/*pharmacology | 2 | 4.0 |
Cell Movement | 2 | 0.0 |
Age of Onset | 2 | 0.0 |
B-Lymphocytes/*physiology | 4 | 2.0 |
Tonsil/cytology | 3 | 3.0 |
Antibodies, Monoclonal | 16 | 0.0 |
Carbohydrate Sequence | 2 | 0.0 |
T-Lymphocytes/immunology/*metabolism | 2 | 2.0 |
Blotting, Southern | 6 | 0.0 |
Cloning, Molecular | 7 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Species Specificity | 3 | 0.0 |
Gene Expression | 8 | 0.0 |
Oligonucleotide Array Sequence Analysis/*methods | 2 | 1.0 |
Italy/epidemiology | 2 | 0.0 |
Models, Immunological | 2 | 0.0 |
Cell Line | 13 | 0.0 |
*Gene Expression | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Time Factors | 7 | 0.0 |
Up-Regulation | 2 | 0.0 |
B-Lymphocytes/*pathology | 2 | 4.0 |
Cell Division/physiology | 2 | 0.0 |
Histocytochemistry | 2 | 0.0 |
Mice, Nude | 3 | 0.0 |
Tumor Stem Cell Assay | 2 | 1.0 |
B-Lymphocytes/*immunology | 14 | 1.0 |
Cell Separation | 7 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Disease-Free Survival | 3 | 0.0 |
Remission Induction/methods | 2 | 8.0 |
Antigens, CD/*analysis/immunology | 2 | 6.0 |
Cell Membrane/immunology | 4 | 1.0 |
Neutrophils/*immunology | 4 | 2.0 |
Child | 16 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Gene Rearrangement | 6 | 1.0 |
Microscopy, Electron | 6 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
*Tumor Cells, Cultured | 2 | 2.0 |
Cell Adhesion Molecules/*immunology | 2 | 3.0 |
Cell Differentiation | 8 | 0.0 |
Gene Rearrangement, B-Lymphocyte | 2 | 3.0 |
Genes, Immunoglobulin | 2 | 1.0 |
Antigens, CD/*analysis | 15 | 1.0 |
Flow Cytometry/methods | 4 | 1.0 |
Tumor Markers, Biological/analysis | 4 | 0.0 |
Cell Division/drug effects | 3 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Mice, Inbred C3H | 2 | 0.0 |
Bone Marrow/pathology | 4 | 1.0 |
Chromosome Disorders | 3 | 0.0 |
Chromosomes, Human, Pair 14 | 5 | 3.0 |
Chromosomes, Human, Pair 18 | 3 | 2.0 |
Mice, SCID | 4 | 0.0 |
Neoplasm Transplantation | 3 | 0.0 |
Translocation, Genetic | 3 | 0.0 |
Transplantation, Heterologous | 3 | 0.0 |
Antigens, Differentiation/analysis | 7 | 2.0 |
Spleen/cytology | 3 | 1.0 |
*Chromosome Aberrations | 2 | 0.0 |
Alleles | 4 | 0.0 |
Bone Marrow Cells | 9 | 2.0 |
Chromosome Mapping | 3 | 0.0 |
*Lymphocyte Activation | 2 | 0.0 |
Mice, Inbred BALB C | 6 | 0.0 |
Thymus Gland/cytology | 2 | 2.0 |
DNA Primers | 3 | 0.0 |
Platelet Activation | 2 | 1.0 |
Bone Marrow/immunology | 3 | 2.0 |
Fluorescent Antibody Technique | 15 | 0.0 |
3T3 Cells | 3 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Pregnancy | 7 | 0.0 |
Antibodies, Monoclonal/immunology | 4 | 0.0 |
Organ Specificity | 3 | 0.0 |
*Antigens, CD | 4 | 0.0 |
Gestational Age | 4 | 0.0 |
Rabbits | 3 | 0.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Dendritic Cells/*immunology | 2 | 0.0 |
Epitopes/*immunology | 2 | 0.0 |
Signal Transduction | 3 | 0.0 |
Antigens, CD/*blood | 4 | 2.0 |
*Antigens, Neoplasm | 2 | 1.0 |
B-Lymphocytes/immunology | 9 | 1.0 |
T-Lymphocytes/immunology | 5 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
Antigens, CD/immunology | 2 | 0.0 |
Cell Survival | 2 | 0.0 |
Child, Preschool | 11 | 0.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Cell Differentiation/immunology | 3 | 0.0 |
Molecular Weight | 4 | 0.0 |
Hematopoietic Stem Cells/*immunology | 3 | 2.0 |
Antigens, Differentiation, B-Lymphocyte/*analysis | 4 | 6.0 |
Immunoglobulin M/analysis | 2 | 0.0 |
ADP-ribosyl Cyclase | 2 | 0.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
Phenotype | 24 | 0.0 |
Antigens, CD | 2 | 1.0 |
Antigens, CD/biosynthesis/*genetics | 2 | 7.0 |
Colony-Forming Units Assay | 2 | 0.0 |
Biopsy | 2 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Cell Membrane/metabolism | 3 | 0.0 |
Phosphorylation | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 4 | 0.0 |
Cell Count | 3 | 0.0 |
*Chromosomes, Human, Pair 11 | 2 | 0.0 |
*Translocation, Genetic | 3 | 0.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Tumor Cells, Cultured/immunology | 2 | 2.0 |
Kidney Transplantation/*adverse effects | 2 | 3.0 |
Neoplasm Staging | 6 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Receptors, Interleukin-2/biosynthesis | 2 | 1.0 |
Antibodies, Monoclonal/therapeutic use | 3 | 1.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Antigens, CD19 | 5 | 3.0 |
Erythrocytes/chemistry | 2 | 4.0 |
Hemoglobinuria, Paroxysmal/*blood | 2 | 7.0 |
Lymphocytes/immunology | 2 | 0.0 |
Multiple Myeloma/*immunology | 3 | 8.0 |
Genes, myc | 2 | 0.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Antigens, Neoplasm/*analysis | 9 | 2.0 |
Fetus | 3 | 0.0 |
Antigens, CD14 | 2 | 0.0 |
Antigens, Differentiation, Myelomonocytic/*analysis | 2 | 1.0 |
Predictive Value of Tests | 3 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Antigens, CD/*biosynthesis | 4 | 2.0 |
Rats, Wistar | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
*Bone Marrow Transplantation | 3 | 0.0 |
Cytotoxicity, Immunologic | 3 | 0.0 |
Transplantation, Autologous | 4 | 1.0 |
Bone Marrow/*pathology | 2 | 1.0 |
Multiple Myeloma/*pathology | 2 | 3.0 |
Paraproteinemias/*pathology | 2 | 33.0 |
Tonsil/pathology | 2 | 12.0 |
Antigens, CD11 | 2 | 2.0 |
Intercellular Adhesion Molecule-1 | 2 | 0.0 |
Temperature | 2 | 0.0 |
Disease Progression | 3 | 0.0 |
Regression Analysis | 2 | 0.0 |
Frozen Sections | 2 | 2.0 |
Skin/*pathology | 2 | 2.0 |
B-Lymphocytes/*metabolism | 2 | 1.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Antigens, CD13 | 2 | 3.0 |
Antigens, CD3/biosynthesis | 2 | 3.0 |
Antibodies, Monoclonal/*therapeutic use | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/immunology | 3 | 5.0 |
Herpesvirus 4, Human | 2 | 1.0 |
Receptors, Fc/immunology | 2 | 4.0 |
Receptors, IgE | 2 | 3.0 |
Recurrence | 2 | 0.0 |
Gene Rearrangement, T-Lymphocyte | 2 | 1.0 |
Immunoglobulins, Heavy-Chain/genetics | 2 | 1.0 |
Remission Induction | 2 | 0.0 |
Antigens, CD45 | 4 | 1.0 |
Chromosome Aberrations | 3 | 0.0 |
Immunoglobulins, Heavy-Chain/*genetics | 4 | 2.0 |
Lymphoma, Non-Hodgkin/classification/immunology/*pathology | 2 | 50.0 |
Antigens, CD/*physiology | 3 | 0.0 |
Antigens, CD20 | 2 | 2.0 |
Antigens, CD40 | 3 | 5.0 |
Cell Adhesion Molecules/physiology | 2 | 2.0 |
Protein-Tyrosine Kinase/*physiology | 2 | 1.0 |
Antibodies, Monoclonal/*diagnostic use | 3 | 1.0 |
Neprilysin | 7 | 9.0 |
Glycolipids/physiology | 2 | 33.0 |
Glycosylphosphatidylinositols | 4 | 7.0 |
Phosphatidylinositols/physiology | 2 | 20.0 |
Receptors, Cell Surface/*physiology | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Leukemia, Myelocytic, Acute/immunology/*pathology | 2 | 15.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 4 | 1.0 |
DNA/analysis | 2 | 0.0 |
*Signal Transduction | 2 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 15 | 1.0 |
Antigens, Differentiation/*analysis | 5 | 2.0 |
Immunoglobulin G/analysis | 2 | 0.0 |
Antigens, Surface/immunology | 3 | 1.0 |
Receptors, Complement/analysis | 2 | 3.0 |
Antigens, Surface/analysis | 7 | 1.0 |
Antigens, Neoplasm/*immunology | 2 | 1.0 |
Antigens, CD5 | 2 | 0.0 |
Gene Rearrangement/genetics | 2 | 4.0 |
*Cell Line | 2 | 4.0 |
Antigens, CD56 | 2 | 2.0 |
Antigens, Differentiation/*immunology | 2 | 1.0 |
Antigens, Neoplasm/immunology | 2 | 1.0 |
Receptors, IgG | 2 | 1.0 |
Brain Neoplasms/prevention & control | 2 | 66.0 |
Antibodies, Monoclonal/*immunology | 3 | 0.0 |
Cell Nucleus/pathology | 2 | 2.0 |
Cytoplasm/pathology | 2 | 7.0 |
Antigens, Differentiation/*physiology | 2 | 2.0 |
Brain/*metabolism | 2 | 0.0 |
Leukemia, B-Cell, Chronic/*immunology | 2 | 4.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2.0 |
*Genes, Immunoglobulin | 2 | 1.0 |
Platelet Count | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte | 3 | 8.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 3 | 1.0 |
Bone Marrow/immunology/pathology | 2 | 5.0 |
Neoplasm Invasiveness | 3 | 0.0 |
Complement/immunology | 2 | 2.0 |
Leukemia, Lymphocytic/*therapy | 2 | 40.0 |
Complement/*immunology | 2 | 1.0 |
Cluster Analysis | 2 | 1.0 |
